The Disruptors: What’s Next for Cell Therapy in Liquid Tumors?

Since 2017 six CAR-T therapies have been approved by the FDA for a number of liquid tumors and these therapies have produced remarkable results for patients. In many respects these are all first generation agents and this raises the question of where does the field go next? Dual or n-plexed targeting, side effect reduction, use of different T-cell subtypes and alternative applications outside of cancer are among the possibilities. This panel of experts will discuss their view of where is this evolving field is heading.

The Disruptors: What’s Next for Cell Therapy in Liquid Tumors?

Grand Ballroom